Bristol-Myers Squibb Reports Results of Opdivo (nivolumab) in P-III CheckMate-459 Study as 1L Treatment for Patients with Unresectable Hepatocellular Carcinoma

Bristol-Myers Squibb Reports Results of Opdivo (nivolumab) in P-III CheckMate-459 Study as 1L Treatment for Patients with Unresectable Hepatocellular Carcinoma

Shots:

  • The P-III CheckMate-459 study results involve assessing of Opdivo vs sorafenib as a 1L treatment in patients with unresectable hepatocellular carcinoma (HCC)
  • The P-III CheckMate-459 study results demonstrated that it did not meet its 1EPs of overall survival (OS) per the pre-specified analysis, no new safety signals were observed
  • Opdivo is PD-1 immune check inhibitor, harnessing the body’s own immune system to help restore anti-tumor immune response, being evaluated in multiple studies for HCC as monothx. or in combination with Yervoy (ipilimumab) for prior treated patients

Click here to read full press release/ article | Ref: BMS | Image: Record Journal